Bevacizumab plus erlotinib compared to erlotinib on it's own inside Japanese patients together with innovative, metastatic, EGFR-mutant non-small-cell carcinoma of the lung (NEJ026): overall survival investigation of your open-label, randomised, multicentre, period Three or more test.
